North Alabama Homebuilding Academy gets $500,000 grant
HUNTSVILLE, Ala. (WHNT) — A Huntsville non-profit focused on offering hands-on skills training for people looking to start a career in residential construction, recently got a big boost.
The North Alabama Homebuilding Association (NAHA), is one of only 15 non-profits across the country, to be a recent recipient of a Lowe's Foundation Gables Grant. NAHA received a $500,000 grant.
Alabama service member comes home and surprises his kids
'We're just absolutely ecstatic about it,' said Larry Durham, the owner of Durham Service Company and the Chairman of the North Alabama Homebuilding Academy Foundation.
Durham explained that the grant money will go towards expanding NAHA's workforce development program throughout the state of Alabama.
'It's going to be used as seed money to start up more satellite programs around the state,' Durham said.
NAHA offers classes and courses to train people who are interested in pursuing a career in the residential construction industry. Durham explained that there's a major shortage of new people joining the industry.
Muscle Shoals welcomes new fire chief
'The average age of a journeyman plumber, electrician, carpenter, HVAC technician in state of Alabama is 57 years old,' Durham said. 'For every five the industry is losing, we're only gaining one back. The demand has never been greater for skilled construction services, and we're trying to do our best to rebuild that,'
The Lowe's Foundation Gable Grants program has a similar goal.
'When we talk to our professionals out in the field, 9 out of 10 tell us, that they have trouble finding the workers they need,' Director of the Lowe's Foundation Betsy Conway said. 'So, being able to address this worker shortage crisis through these local programs like NAHA is really critical.'
The Lowe's Foundation has pledged to donate $50 million dollars to organizations that support training programs in carpentry, construction, HVAC, electrical, plumbing, and appliance repair. So far, the foundation says it has awarded $34 Million in Gable Grants towards that goal.
Durham told News 19 that working with the Lowe's Foundation on the grant was a great process. He said NAHA originally applied for a $250,000 grant, but that quickly changed.
'What was astounding, is when Lowe's called us back and asked us if we could use an additional $250,000,' said Durham.
That doubled their grant to a total of $500,000.
Conway said the foundation was so impressed with NAHA's work that they had to double the funding.
'When I was on the call and NAHA started walking through all of their plans, the foundation board, which is a part of this process, was so impressed by their plans for future growth that after the call, we actually decided to go back to not and say, 'look, if we were able to provide you with more funding, what more could you do?'' Conway said. 'This expansion plan came back and we are just thrilled to be able to make this happen.'
'I think what NAHA is doing in northern Alabama, how they're now going to be able to replicate their program across the entire state, is a best practice that I hope many will replicate' Conway added.
Durham told News 19 that NAHA plans to work with the state homebuilders association and other partners to get the ball rolling on expanding programming statewide.
Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles

Yahoo
18 hours ago
- Yahoo
Dye & Durham shakes up C-suite with new picks, ignores former CEO's demands
By Svea Herbst-Bayliss and Kritika Lamba (Reuters) -Dye & Durham on Monday announced a dramatic shift in leadership when it named a new chief executive and a new chief financial officer, ignoring demands from a former chief who is also a large investor to pursue a different course. The Canadian legal software maker appointed former LexisNexis executive George Tsivin as chief executive and brought back Avjit Kamboj to reprise his role as chief financial officer. It also hired Nikesh Patel as chief product officer. "After an in-depth and diligent search, we have assembled a world-class leadership team to guide the company through its next chapter," board chair Arnaud Ajdler said in a statement. Kamboj, who left Dye & Durham in 2022, guided the company's financial strategy during its initial public offering and significant growth stages. The announcement comes two weeks after a former Dye & Durham CEO, Matthew Proud, urged the company to stop searching for a new chief and permanently hand the job to the man doing it already in an interim capacity. More importantly, Proud, whose company Plantro Ltd controls 12% of Dye & Durham, urged a board refresh and is pushing the company to divest the financial services division and then begin work on selling the remaining core business. He also said he is ready to call a special shareholder meeting unless the board considers the changes he is proposing. He stepped down from the CEO position six months ago. Dye & Durham's financial performance has worsened, Proud said on Monday, as earnings have dropped against a backdrop of higher costs and flat revenue. The company has not publicly responded to Proud's criticisms. The company last month reported third quarter fiscal 2025 earnings and its stock price tumbled 50% in the last six months, valuing the company at roughly $490 million. The stock price fell nearly 2% in early trading on Monday. At December's annual meeting, activist investor Engine Capital, run by Ajdler, won control of the board through a proxy fight. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data


Associated Press
a day ago
- Associated Press
Humacyte Clinical Results in High-Risk Dialysis Patients from V007 Pivotal Phase 3
DURHAM, N.C., June 02, 2025 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissue at commercial scale, announced that its abstract on the V007 Pivotal Phase 3 clinical trial of the acellular tissue engineered vessel (ATEV™) in arteriovenous access for high-risk patients with end-stage renal disease was accepted for an oral presentation at the Society for Vascular Surgery Vascular Annual Meeting (VAM25). The abstract titled 'Acellular Tissue Engineered Vessel Outperforms Arteriovenous Fistula in High-Risk Patients on Hemodialysis: Results from the CLN-PRO-V007 Randomized Controlled Trial' will be presented at the VAM25 meeting in New Orleans this Friday, June 6, 2025. Details of the presentation are as follows: Presentation Title: 'Acellular Tissue Engineered Vessel Outperforms Arteriovenous Fistula in High-Risk Patients on Hemodialysis: Results from the CLN-PRO-V007 Randomized Controlled Trial' Presenter: Dr. Mohamad A. Hussain, MD, PhD, RPVI, FAHA, FRCSC, FACS, Vascular and Endovascular Surgeon-Scientist at Brigham and Women's Hospital, Core Faculty at the Center for Surgery and Public Health, and Assistant Professor of Surgery at Harvard Medical School Session Title: Plenary Session 6 Session Date/Time: Friday, June 6, 2025, 10:50 a.m. CT For more information on the Society for Vascular Surgery Vascular Annual Meeting (VAM25), please click here. About Humacyte Humacyte, Inc. (Nasdaq: HUMA) is developing an innovative biotechnology platform to deliver universally implantable bioengineered human tissues, advanced tissue constructs, and organ systems designed to improve the lives of patients and transform the practice of medicine. The Company develops and manufactures acellular tissues designed to treat a wide range of diseases, injuries, and chronic conditions. Humacyte's Biologics License Application for the acellular tissue engineered vessel (ATEV) in the vascular trauma indication was approved by the FDA in December 2024. ATEVs are also currently in late-stage clinical trials targeting other vascular applications, including arteriovenous (AV) access for hemodialysis and peripheral artery disease (PAD). Preclinical development is also underway in coronary artery bypass grafts, pediatric heart surgery, treatment of type 1 diabetes, and multiple novel cell and tissue applications. Humacyte's 6mm ATEV for AV access in hemodialysis was the first product candidate to receive the FDA's Regenerative Medicine Advanced Therapy (RMAT) designation and has also received FDA Fast Track designation. Humacyte's 6mm ATEV for urgent arterial repair following extremity vascular trauma and for advanced PAD also have received RMAT designations. The ATEV received priority designation for the treatment of vascular trauma by the U.S. Secretary of Defense. For more information, visit For uses other than the FDA approval in the extremity vascular trauma indication, the ATEV is an investigational product and has not been approved for sale by the FDA or any other regulatory agency. Humacyte Investor Contact: Joyce Allaire LifeSci Advisors LLC +1-617-435-6602 [email protected] [email protected] Humacyte Media Contact: Rich Luchette Precision Strategies +1-202-845-3924 [email protected] [email protected]
Yahoo
2 days ago
- Yahoo
Cooper Flagg's Stunning Duke NIL Earnings Revealed
Cooper Flagg's Stunning Duke NIL Earnings Revealed originally appeared on Athlon Sports. During his lone season with the Duke Blue Devils, former No. 1 overall recruit Cooper Flagg lived up to the billing as the next great American prospect. Advertisement Although he and the Blue Devils fell in the Final Four to the eventual runner-up Houston Cougars, Flagg led Duke in all five major statistical categories en route to a 35-4 record. In addition to being named ACC Player of the Year, Flagg also became the ninth Duke player to be named Naismith Men's College Player of the Year. Aside from prospering on the court, many fans likely assumed that Flagg was compensated quite well off of it, thanks to his NIL earning potential. Although it's not always an exact number, his NIL Valuation according to On3 was a staggering $4.8 million. A mark that only trailed Texas quarterback and nephew of Peyton Manning, Arch Manning. However, as revealed during an interview with Bob Costas by insider and author Howard Bryant, Flagg's earnings were significantly higher than the estimated numbers. Duke Blue Devils forward Cooper Flagg (2).Vincent Carchietta-Imagn Images After initially asking Costas how much money he thought Flagg brought in during his lone season in Durham, Bryant answered his own question with a jaw-dropping figure. As a result of Flagg inking monster deals with New Balance and Fanatics, he was bringing in at least $28 million on the year. Advertisement "He had a $13 million deal with New Balance and then $15 million with Fanatics," Bryant said. A staggering mark, considering an April report revealed that at least eight teams in college basketball will spend over $10 million on their entire roster for next season. While around $30 million is chump change by any means, Flagg's earnings will more than double following next month's NBA Draft. Flagg has been projected to be the top pick for over a year, and now that the Dallas Mavericks have the pick, the safest assumption in the world is that he will be heading to the Lone Star State. According to Spotrac, the No. 1 pick is set to sign a four-year deal worth nearly $63 million. Turns out being a generational basketball prospect pays quite well, who knew? Related: Cooper Flagg Makes Big Career Move Before NBA Draft This story was originally reported by Athlon Sports on May 31, 2025, where it first appeared.